NO995938L - Blanding omfattende 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion - Google Patents

Blanding omfattende 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion

Info

Publication number
NO995938L
NO995938L NO995938A NO995938A NO995938L NO 995938 L NO995938 L NO 995938L NO 995938 A NO995938 A NO 995938A NO 995938 A NO995938 A NO 995938A NO 995938 L NO995938 L NO 995938L
Authority
NO
Norway
Prior art keywords
thiazolidine
dione
pyridyl
ethoxy
benzyl
Prior art date
Application number
NO995938A
Other languages
English (en)
Norwegian (no)
Other versions
NO995938D0 (no
Inventor
Jai Patel
Hamish Ross
Jeffrey Roger Granett
Robin Price
Paul Nigel Wray
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO995938D0 publication Critical patent/NO995938D0/no
Publication of NO995938L publication Critical patent/NO995938L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO995938A 1997-06-05 1999-12-03 Blanding omfattende 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion NO995938L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
NO995938D0 NO995938D0 (no) 1999-12-03
NO995938L true NO995938L (no) 2000-02-02

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
NO995938A NO995938L (no) 1997-06-05 1999-12-03 Blanding omfattende 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
NO20040738A NO20040738L (no) 1997-06-05 2004-02-20 Blanding omfattende 5- [4- [2- (N-metyl-N-2-pyridyl])-amino) etoksyl] bensyl] tiazolidin-2,4-dion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20040738A NO20040738L (no) 1997-06-05 2004-02-20 Blanding omfattende 5- [4- [2- (N-metyl-N-2-pyridyl])-amino) etoksyl] bensyl] tiazolidin-2,4-dion.

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1112926C (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR200002790T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA984826B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CO5170421A1 (es) 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto farmaceutico maleico
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0777469A1 (en) * 1994-02-10 1997-06-11 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
CN1230114A (zh) * 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法

Also Published As

Publication number Publication date
OA11306A (en) 2003-10-22
IL133074A0 (en) 2001-03-19
BG104048A (bg) 2000-07-31
GB9711683D0 (en) 1997-08-06
NZ513922A (en) 2001-09-28
CN1430959A (zh) 2003-07-23
TW570797B (en) 2004-01-11
CN1112926C (zh) 2003-07-02
BR9810405A (pt) 2000-08-29
TR200002790T2 (tr) 2001-11-21
KR20010013410A (ko) 2001-02-26
CA2292629C (en) 2004-01-06
TR199902963T2 (xx) 2000-02-21
HUP0004070A2 (hu) 2002-02-28
ZA9811572B (en) 1999-07-22
AP1214A (en) 2003-10-08
DZ2510A1 (fr) 2003-01-25
NO995938D0 (no) 1999-12-03
AR008198A1 (es) 1999-12-29
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28
CN1259050A (zh) 2000-07-05
NO20040738L (no) 2000-02-02
UY25032A1 (es) 1998-11-26
CO4940400A1 (es) 2000-07-24
AP9901696A0 (en) 1999-12-31
AU8215098A (en) 1998-12-21
CA2292629A1 (en) 1998-12-10
NZ523725A (en) 2004-09-24
AR015120A1 (es) 2001-04-18
ZA984826B (en) 1999-08-03
EA199901116A1 (ru) 2000-06-26
CN1526391A (zh) 2004-09-08
PL337201A1 (en) 2000-08-14
CA2333352A1 (en) 1998-12-10
MXPA99011322A (es) 2004-12-02
ID24264A (id) 2000-07-13
EP0998284A1 (en) 2000-05-10
PE78899A1 (es) 1999-10-22
WO1998055122A1 (en) 1998-12-10
EA002384B1 (ru) 2002-04-25
SK164899A3 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
NO20024307D0 (no) Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
RS51343B (sr) Nova kompozicija i njena upotreba
NO2001005I2 (no) 5-Ä4-Ä2-(N-metyl-N-(2-pyridyl)amino)etoksy)benzyl)tiazolidin-2,4dion, maleinsyresalt
FI933804A (fi) Monohydrat av 5-(2-(4-(1,2-bensisotiazol-3-yl)-1-piperazinyl)etyl-6-klor-1,3-dihydro-2H-indol-2-onkhydroklorid
NO995938L (no) Blanding omfattende 5-[4-[2-(N-metyl-N-2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
IL136424A0 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AP2000001830A0 (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
DK0927173T3 (da) Substituerede [2-(1-piperazinyl)ethoxy]methylforbindelser
DK1315723T3 (da) Hydrochloridsaltet af 5[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion
AU2002343036A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
IL160144A0 (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione
AU6255001A (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application